Robert A. Berman

Chief Executive Officer at enVVeno Medical

Board

Since April 30, 2018

Age

62 years

Education

Holds a B.S. in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and a J.D. from Northwestern University School of Law.

Tenure

Joined NVNO as Chief Executive Officer and Board member in April 2018 and has overseen strategic transitions since then.

Also at enVVeno Medical

Craig Glynn

Chief Financial Officer and Treasurer

DHA

Dr. Hamed Alavi

Senior Vice President and Chief Technology Officer

MHG

Marc H. Glickman

Senior Vice President and Chief Medical Officer

About

Robert A. Berman is an experienced executive with over 25 years in healthcare, finance, and technology, and is currently 62 years old as per the latest reports.

Before joining NVNO, he held senior leadership roles at Acacia Research Corporation and ITUS Corporation, where he played key roles in transforming business strategies and operational frameworks.

Since his appointment in April 2018, and specifically as Chief Executive Officer from April 30, 2018, he has managed risk oversight, corporate strategy, and significant operational reforms, further extending his influence through academia as an adjunct faculty member.

$NVNO Performance Under Robert A. Berman

Past Roles

Organization	Role	Date Range	Details
ITUS Corporation (now Anixa Biosciences)	President, Chief Executive Officer, and Board Director	September 2012 - July 2017	Transitioned the company from a flat panel display developer to a Nasdaq-listed cancer therapeutics company
Acacia Research Corporation	Chief Operating Officer and General Counsel	2000 - March 2007	Transitioned the company from an incubator of internet startups to a publicly traded company with market capitalization exceeding $2 billion
Blank Rome	Early Career Role	N/A	Started his career at this law firm

External Roles

Organization	Role	Date Range	Details
Northwestern University School of Law	Adjunct Faculty Member	N/A	Holds an adjunct position at the School of Law

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Salary	$500,000	Annual (Fiscal Year Ended Dec 31, 2024)	Fixed annual salary
Option Awards	$400,513	Vests quarterly over 3 years	200,000 stock options granted on Dec 18, 2024; computed per FASB ASC Topic 718
Other Compensation	$28,119	Annual	Includes company-paid healthcare of $9,679 and a 401(k) match of $18,441

Performance Compensation

Data from FY 2024

Bonus

Metric	Value
Amount ($USD)	$232,500
Eligible as (% of Base Salary)	Up to 60%
Performance Metrics	Key Performance Indicators (KPI); specifics not disclosed
Evaluation Period	Fiscal 2024
Payout Timing	Annual

Restricted Stock Units (RSUs)

Metric	Value
Number of RSUs	200,000
Market Value as of 12/31/2024 ($USD)	$604,000
Performance Requirement	Pre-Market Approval of the VenoValve
Vesting Condition	Entire lot vests upon achieving the milestone
Additional Details	SAVVE condition removed on 12/05/2023; RSUs originally subject to dual milestones